TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03133169

Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid regurge velocity
Description: Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
Study: NCT01637935

Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study: NCT03164135

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CCR5 gene modification
Description: CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
Study: NCT03064984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBS eyedrops
Description: CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBS eyedrops
Description: PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
Study: NCT02092831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 3
Study: NCT03627494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT02092831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose Phase 2 tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose Phase 2 tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose Phase 2 tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose Phase 2 tablet formulation
Study: NCT02545738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00804817

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCION-HSCT program
Description: Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects.
Study: NCT06338735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-High Frequency Ultrasound scan of minor salivary glands
Description: Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
Study: NCT04219735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT02624726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
Study: NCT01320748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Processing
Description: A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
Study: NCT00136318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
Study: NCT00787579

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal spectacles
Description: +1.50D bifocal spectacles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prismatic bifocal spectacles
Description: +1.50D bifocal spectacles combined with 3Δ base-in prisms
Study: NCT03670160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
Study: NCT00577278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo APBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study: NCT03399669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
Study: NCT01850511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibrissae trimming
Description: Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of oxymetazoline
Description: Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
Study: NCT00967434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
Study: NCT01348217

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node
Description: 40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node
Description: 40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Boost
Description: Boost 10 Gy in 5 fr, PTV = +1cm.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost
Description: Boost 26 Gy in 13 fr, PTV = +1cm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: FOLFOX 4
Description: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: FOLFOX 4
Description: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
Study: NCT02038569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel
Study: NCT04187599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragon CRT®100 Contact Lens
Description: Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
Study: NCT01255670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: penicillin and metronidazole in peritonsillar abscess
Description: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: penicillin and metronidazole in peritonsillar abscess
Description: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
Study: NCT04706052

Intervention type: OTHER
Intervention: Superficial Parotidectomy
Description: Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
Study: NCT04255290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Squat Lounge
Description: The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The subjects included in the control group will perform an eccentric work protocol
Study: NCT03016221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axanova hot gel
Description: Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axanova activ gel
Description: Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Dolo Gel
Description: Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Classic Gel
Description: Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Cool Kühl-Gel
Description: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Hot Gel
Description: Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
Study: NCT01037985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT03016221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Classic Gel
Description: Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Cool Gel
Description: Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
Study: NCT03898895

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy+anti-PD-1 antibody
Description: The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
Study: NCT02273336

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo tissue and blood sample collection
Study: NCT03623334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy
Description: Radiotherapy to a potent tumorcidal dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy
Description: Radiotherapy to a potent tumorcidal dose
Study: NCT02273336

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02701166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: bezafibrate 400mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400mg per day
Study: NCT03235661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
Study: NCT00172536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
Study: NCT01703936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agricultural and life skills training program
Study: NCT01037985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT04487002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Study: NCT00817076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine syrup; 5.0 mL once daily for 28 days
Study: NCT00085774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol aerosol by HFA MDI
Description: albuterol HFA MDI 160 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol aerosol by HFA BOI
Description: albuterol HFA BOI 160 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo aerosol by HFA
Description: placebo HFA
Study: NCT03858595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain
Description: Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis.
Study: NCT01201941

Intervention type: OTHER
Intervention: e-Chasqui
Description: The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests.
Study: NCT04002336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Voice therapy
Description: Traditional method of voice therapy
Study: NCT01030107

Intervention type: BEHAVIORAL
Intervention: Increase Sleep
Description: Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
Study: NCT04002336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Therapy App
Description: Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
Study: NCT00577278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study: NCT03965403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm motor function retraining with BURT
Description: Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
Study: NCT01030107

Intervention type: BEHAVIORAL
Intervention: Decrease Sleep
Description: Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
Study: NCT03664960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.